Cardiac substructures exposure in left-sided breast cancer radiotherapy: Is the mean heart dose a reliable predictor of cardiac toxicity?
Adult
Aged
Aged, 80 and over
Carcinoma, Ductal, Breast
/ drug therapy
Carcinoma, Lobular
/ drug therapy
Cardiotoxicity
/ etiology
Coronary Vessels
/ radiation effects
Female
Heart
/ radiation effects
Heart Atria
/ radiation effects
Heart Ventricles
/ radiation effects
Humans
Lymphatic Irradiation
Middle Aged
Organs at Risk
/ radiation effects
Prospective Studies
Radiation Dosage
Radiation Dose Hypofractionation
Radiotherapy, Conformal
/ adverse effects
Re-Irradiation
Unilateral Breast Neoplasms
/ drug therapy
Breast cancer
Cancer du sein
Cardiac dosimetry
Cardio-oncologie
Cardio-oncology
Dosimétrie cardiaque
Radiotherapy
Radiothérapie
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
18
06
2020
revised:
11
07
2020
accepted:
03
09
2020
pubmed:
12
1
2021
medline:
14
5
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
This study aimed to assess radiation dose distribution to cardiac subvolumes in left-sided breast cancer radiotherapy (LBCRT) and to clarify whether the mean heart dose (MHD) reliably reflects cardiac substructures exposure. Fifty women referred for adjuvant LBCRT were prospectively evaluated. All patients received 3D-conformal hypofractionated radiotherapy (40Gy delivered in 15 fractions of 2.67Gy±boost of 13.35Gy). Cardiac substructures were contoured using the F. Duane's cardiac atlas. Dose distribution to cardiac chambers, left main (LM), left anterior descending (LAD), left circumflex (LCx) and right coronary artery (RCA)) was assessed. Dosimetric associations were analysed. The mean MHD was 3.08Gy (EQD2=3.67Gy). The mean Dmean/Dmax LAD was 11.45Gy (EQD2=13.64Gy)/29.5Gy (EQD2=35.15Gy). Low doses were delivered to LM, LCx, and RCA (Dmean≤1.3Gy). The left ventricle (LV) was the most exposed cardiac chamber with Dmean/Dmax of 4.78Gy/37Gy. The strongest correlation with MHD was found for Dmean LAD (r=0.81). For every 1Gy increase in MHD, Dmean LAD rose by 3.4Gy. However, the proportion of variance in Dmean LAD predictable from MHD was moderate (R Our study showed high exposure of LAD and LV in LBCRT. With poor predictive value, MHD may underestimate doses to cardiac substructures. For optimal heart sparing radiotherapy, we recommend to consider LV and LAD as separate organ at risk.
Identifiants
pubmed: 33423965
pii: S1278-3218(20)30353-X
doi: 10.1016/j.canrad.2020.09.003
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-236Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.